ORIGINAL RESEARCH
Tadalafil Is Efficacious and Well Tolerated in the Treatment of Erectile Dysfunction (ED) in Men over 65 Years of Age: Results from Multiple Observations in Men with ED in National Tadalafil Study in the United States

https://doi.org/10.1111/j.1743-6109.2007.00712.xGet rights and content

ABSTRACT

Introduction

Erectile dysfunction is increasingly common with advancing age, yet sexual activity and intimacy are important to elderly men.

Aim

To assess the efficacy and tolerability of tadalafil in men over the age of 65 years.

Method

In this multicenter open-label study, 188 men (mean age = 71.6 years) who were over age 65 and did not have diabetes mellitus or clinical depression received tadalafil 20 mg, taken on demand, for up to 12 weeks.

Main Outcome Measures

Efficacy was assessed using the International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP). Psychosocial outcomes were evaluated using the Psychological and Interpersonal Relationship Scale (PAIRS).

Results

Tadalafil treatment significantly improved all domains of the IIEF from baseline, including the erectile function (EF) domain (change = 8.8, end point = 21.6; P < 0.001). Mean per-patient percentage of “yes” responses to SEP questions concerning successful penetration (SEP2; change = 33.5%, end point = 73.5%; P < 0.001) and successful intercourse (SEP3; change = 39.6%, end point = 59.6%; P < 0.001) also improved significantly from baseline. Forty percent of the patients with baseline EF scores <26 had normal EF (IIEF-EF domain scores ≥26) at end point, and 81% reported improved erections in the Global Assessment Questionnaire. At least 56% of attempts at sexual intercourse were successfully completed (SEP3) at all time intervals up to 36 hours after tadalafil administration. The patients also experienced significant improvement in both the sexual self-confidence and spontaneity domains of the PAIRS. Tadalafil was well tolerated, with <5% of the patients discontinuing because of adverse events.

Conclusion

Tadalafil 20 mg was effective and well tolerated in elderly men with ED. Sharlip ID, Shumaker BP, Hakim LS, Goldfischer E, Natanegara F, and Wong DG. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: Results from Multiple Observations in Men with ED in National Tadalafil Study in the United States.

Introduction

Erectile dysfunction (ED), the persistent inability to achieve and/or maintain an erection adequate for satisfactory sexual activity, is increasingly frequent with advancing age. Age is the clinical variable most strongly correlated with ED. In the Massachusetts Male Aging Study, the probability of complete ED tripled (to 15%) and the probability of moderate ED doubled (to 34%) in men age 70 compared to men age 40 [1]. Only about one in three men aged 70 years reported no erectile difficulties [1].

An increasing likelihood of ED with aging has been observed in the Americas, Europe, the Middle East, Asia, and Australia [2, 3, 4]. Largely because of population aging in industrialized societies, the number of men with ED worldwide has been projected in one study to more than double (to 322 million) from 1995 to 2025 [5]. Approximately 800,000 people across the world reach the age of 65 each month [6].

In addition to advancing age, coronary heart disease, hypertension [7], diabetes mellitus [8], dyslipidemia [9], lower urinary tract symptoms [10], and depression [11] are increasingly common with advancing age and are associated with ED. Treatments for many chronic disorders can also contribute to ED [12], and iatrogenic ED may be particularly relevant in the assessment of elderly patients who are taking multiple medications.

The pathogenesis of ED with aging is multifactorial. However, based on experiments in aged organisms, an important hypothesis that has emerged to explain the development of ED in elderly men and other individuals is decreased nitric oxide (NO)—cyclic nucleotide signaling in the corpus cavernosum [13, 14, 15].

Oral inhibitors of phosphodiesterase type 5 (PDE5), which increase cyclic guanosine monophosphate levels and promote NO-mediated cavernous vascular smooth-muscle-cell relaxation in response to sexual stimulation, are considered first-line therapies for ED. In the integrated analysis of 11 randomized, placebo-controlled trials involving ED patients of varying ages, the selective PDE5 inhibitor tadalafil was effective, safe, and well tolerated [16, 17]. Tadalafil has demonstrated significant improvement in erectile function (EF) for up to 36 hours after dosing [18].

Sexual activity and intimacy remain important to many elderly men well beyond typical reproductive years [19, 20, 21]. Although some men and their partners accept a decline in sexual interest and activity with age [22, 23], large proportions of elderly men remain sexually active and are bothered by ED or report diminished sexual satisfaction, quality of partner relationships, or overall quality of life because of ED [2, 10, 20, 24, 25, 26, 27]. By one estimate [19], 33% of men aged >60 years have sexual activity once weekly.

Data on the efficacy and safety of oral PDE5 inhibitors in the treatment of ED in men aged ≥65 years are limited. In prior pooled subgroup analyses of randomized controlled trials, treatment with either sildenafil citrate 25–100 mg or vardenafil hydrochloride 5–20 mg taken as needed up to once daily for ≥12 weeks improved EF across a number of outcome measures compared with placebo [27, 28]. A total of 17% of men aged ≥65 who received sildenafil (pooled doses) reported headache (vs. 4% with placebo) and 13% flushing (vs. 0% with placebo), while 20% of patients aged ≥65 who received vardenafil 20 mg reported headache (vs. 3% with placebo) and 19% flushing (vs. 0% with placebo) [27, 28].

Section snippets

Aims

The objective of the Multiple Observations in Men with ED in National Tadalafil Study in the United States (MOMENTUS) was to assess the efficacy and tolerability of tadalafil 20 mg, taken as needed for 12 weeks, by various prospectively identified groups of men with comorbid conditions or risk factors for ED, such as diabetes mellitus, depression, spinal cord injury, and older age [29]. Secondary aims included determining changes from baseline in psychosocial outcomes of ED treatment, such as

Study Design and Subjects

This multicenter, open-label study evaluated the efficacy and tolerability of tadalafil 20 mg in various populations of patients with ED, as reported recently by Morgentaler et al. [29]. The following analyses focused on the efficacy and tolerability of tadalafil 20 mg, taken as needed, in men over the age of 65. Other prespecified groups in the MOMENTUS trial included patients of different ethnicities (Caucasian, Black American, Hispanic) or with comorbid conditions (diabetes mellitus,

Efficacy and Psychosocial Measures

The efficacy of tadalafil 20 mg in elderly men was evaluated using the International Index of Erectile Function (IIEF [30]), Sexual Encounter Profile (SEP) diary, and Global Assessment Questionnaire (GAQ). The IIEF was administered after the run-in phase (baseline) and at end point (12 weeks or early discontinuation). The patients completed SEP diaries after each attempt at sexual intercourse. The primary efficacy outcome variable was the mean change from baseline to end point in the EF domain

Statistical Analyses

The analyses of efficacy and psychosocial outcomes were conducted on an intent-to-treat basis; all patients with both baseline and at least one post-baseline observation were included. Responses to the IIEF, SEP, and PAIRS were treated as continuous variables, with summary statistics including the mean. For comparisons of continuous data, two-sided Student's t-tests were conducted to assess the significance of mean changes from baseline at α = 0.05. Responses to the GAQ among patients answering

Patient Characteristics

Patients ranged in age from 66 to 89 (mean = 71.6) years, and the vast majority (97%) had ED for >1 year at baseline (Table 1). Most patients (71%) had moderate or severe ED, and 93 (50%) had two or more comorbidities.

Patient Disposition

Of 188 patients aged >65 years, 166 (88.3%) completed the study. Reasons for discontinuation among these patients included adverse events in nine patients (4.8%), lack of efficacy in five (2.7%), personal conflict in five (2.7%), sponsor decision in two (1.1%), and loss to follow-up

Discussion

Treatment with tadalafil 20 mg demonstrated statistically significant and clinically relevant improvement in EF across a broad range of efficacy outcome measures and was well tolerated in elderly men with ED in the MOMENTUS trial. Following 12 weeks of tadalafil therapy, patients experienced significant improvements from baseline in (i) mean scores on the EF domain and all other IIEF domains and (ii) mean per-patient percentage of “yes” responses to all SEP questions. Significant improvements

Conclusion

Tadalafil 20 mg was an effective and well-tolerated treatment of ED in patients >65 years of age.

Acknowledgments

Assistance in manuscript preparation was provided by Stephen W. Gutkin, Rete Biomedical Communications Corp. (Ridgewood, NJ). The authors thank Adeline Ai Lin Yeo, MS, Lilly Research Laboratories, Eli Lilly and Company, for assistance with statistical analyses and Jeffrey R. Means, PhD, Lilly Research Laboratories, Eli Lilly and Company, for reviewing and commenting on the manuscript. Funding: This study and its report were funded by Lilly ICOS LLC (Indianapolis, IN, and Bothell, WA). The

References (48)

  • R.C. Rosen et al.

    The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction

    Urology

    (1997)
  • J.P. Mulhall

    Deciphering erectile dysfunction drug trials

    J Urol

    (2003)
  • J.C. Cappelleri et al.

    Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function

    Urology

    (1999)
  • D. Hatzichristou et al.

    Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: Integrated analysis of randomized, placebo controlled trials

    J Urol

    (2005)
  • G.A. Broderick et al.

    Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate

    J Sex Med

    (2006)
  • I. Goldstein et al.

    Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: Multiple Observations in Men with Erectile dysfunction in National Tadalafil Study in the US

    J Sex Med

    (2007)
  • J. Buvat et al.

    Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled Use vs. on-demand Regimen Evaluation (SURE) study in 14 European countries

    J Sex Med

    (2006)
  • J.M. Haro et al.

    Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study

    J Sex Med

    (2006)
  • C. Hanson-Divers et al.

    Health outcomes variables important to patients in the treatment of erectile dysfunction

    J Urol

    (1998)
  • R.C. Rosen et al.

    The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population

    Curr Med Res Opin

    (2004)
  • M. Kubin et al.

    Epidemiology of erectile dysfunction

    Int J Impot Res

    (2003)
  • I.A. Aytaç et al.

    The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences

    BJU Int

    (1999)
  • Kinsella K,Velkoff VA.An aging world: 2001. US Census Bureau Series P65/01-1-2001. Washington, DC: US Government...
  • I. Sáenz de Tejada et al.

    Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence

    N Engl J Med

    (1989)
  • Cited by (21)

    • Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires

      2016, Journal of Sexual Medicine
      Citation Excerpt :

      This instrument was used originally for evaluating men with ED treated with Viagra (sildenafil citrate; Pfizer, Mission, KS, USA) compared with controls,80,81 and it was used internationally for men presenting with ED, treated with Viagra, to evaluate their self-esteem, confidence, and relationships82 (evidence level = A-1). The Psychological and Interpersonal Relationship Scale (PAIRS)83 was designed to evaluate the sexual satisfaction of “older” men (>65 years old) who present with ED and choose to use Cialis (tadalafil; Eli Lilly and Co, Indianapolis, IN, USA).83 This instrument was validated in a multicenter open-label study for men without any significant organic etiology to their ED (evidence level = B-1).

    • A Web-Based Survey of Erection Hardness Score and Its Relationship to Aging, Sexual Behavior, Confidence, and Risk Factors in Japan

      2013, Sexual Medicine
      Citation Excerpt :

      Previous observations showing an association between ED and depression may further support our findings, given that depression is known to cause low self‐esteem/confidence [31,32]. Numerous studies demonstrated that PDE5 inhibitors can improve erectile function in men with ED and are well‐tolerated treatments, even in older men [6,33,34]. We found that older men who used PDE5 inhibitors had a higher EHS than men in the same age group who did not, suggesting that the use of PDE5 inhibitors might have resulted in enhancing their sexual confidence.

    • Screening and managing erectile dysfunction in diabetic patients (review)

      2013, Sexologies
      Citation Excerpt :

      As a general rule, detailed explanation of the objectives and safety of the treatment are enough to obtain her active consent and participation. PDEI5s are oral erection medications of first line prescription (Sharlip et al., 2008). As with antidiabetics, antidepressants and sleep medication, it is not possible to issue a prescription of PDEI5 without a corresponding therapeutic strategy.

    • The subjective sexual arousal scale for men (SSASM): Preliminary development and psychometric validation of a multidimensional measure of subjective male sexual arousal

      2011, Journal of Sexual Medicine
      Citation Excerpt :

      In September 2006, 25 in‐depth interviews of men who had taken bremelanotide in clinical trials (N = 15 via telephone), men taking the PDE5 inhibitor tadalafil for the treatment of ED (N = 5 at a focus group facility in New York, NY), and men with no sexual function problems (N = 5 at a focus group facility in New York, NY) were conducted. Men taking tadalafil were selected for the in‐depth interviews based on reports that this long‐acting PDE5 inhibitor had a greater effect on psychological aspects (i.e., self‐confidence, spontaneity) of ED than sildenafil [37-39]. Six of the 15 interviews of men in the bremelanotide group were among men who had been interviewed during phase 1.

    View all citing articles on Scopus
    View full text